Introduction: Viral load suppression is a key determinant of successful anti-retroviral therapy. The study aimed to determine virologic response to Antiretroviral therapy in the large cohort of children and adults living with Human Immune deficiency Virus. Materials and Methods: Viral Load results from the HIV Ribonucleic Acid Polymerase Chain Reaction register of 10,887 children and adults on cART in 4 states in Northern Nigeria between 2017 and 2019 were retrieved and analyzed in the PCR Molecular Laboratory of the Federal Teaching Hospital, Gombe. Results: 10,887 children and adults were analyzed. Males were 28.4% (3094) and 71.6% (7793) females. 2.9% (311); 3.5% (386); 7.3% (797); 65.2% (7098); 14.5% (1583); 5.2% (562) and 1.3% (150) were aged 0 - 9 years, 11 - 18 years; 19 - 25 years, 26 - 45 years; 46 - 55 years; 56 - 65 years and <65 years respectively. This first viral load was primarily routine in 96.3% (10,479). ART combination was Zidovudine/Lamivudine/Nevirapine (AZT/3TC/NVP) in 53.8% (5855/10887), Tenofovir/Lamivudine/Efavirenz (TDF/3TC/EFV) in 44.7% (4864). Prior to viral load testing, 48.5% (5275/10887) had received HAART for 1 - 5 years; 7.4% (811/10887) for 6 months but <1 year; 37.4% (4075) 6 - 10 years and 6.7% (726) for >10 years. The most recent CD4count before viral load request was ≥1000/μL in 7.4% (810/10887); 500 -999/μL in 39.0% (4240); 350 - 499 μL in 22.7% (2466) and <350 μL in 30.9% (3371) in these patients. Viral load was ≥1000 c/mL in 24.8% (2697) of PLHIV tested. Viral load was >1000 c/mL in 26.5% (821/3094) males and 24.1% (1876/7793) females. Viral load was significantly lower among females (p-value 0.007). 50.5% (157/311); 52.1% (201/386); 28.5% (227/797); 23.5% (1670/7098); 19.9% (315/1583); 17.8% (100/562) and 18.0% (27/150) aged 0 - 9 years, 11 - 18 years; 19 - 25 years, 26 - 45 years; 46 - 55 years; 56 - 65 years and <65 years had viral load >1000 c/mL respectively. Viral load was >1000 c/mL in 28.2% (229/811) for those on HAART for 6 months - 1 year and 23.6% (1243/5275) after receiving Highly Active Antiretroviral Therapy (HAART) for 1 - 5 years. 26.3% (1072/4075) and 21.1% (153/726) had viral load > 1000 c/mL after receiving HAART for 6 - 10 and >10 years respectively (p-value 0.001). Conclusion: HIV viral suppression was below the WHO recommended threshold.
References
[1]
Joint United Nations Programme on HIV/AIDS (UNAIDS) Data 2018. UNAIDS, Geneva. https://www.unaids.org/en/resources/documents/2018/unaids-data-2018
[2]
World Health Organisation. HIV/AIDS Regional Office for Africa. https://www.afro.who.int/health-topics/hivaids
[3]
Nigeria HIV/AIDS Indicator and Impact Survey. National Summary Sheet Preliminary Findings. March 2019.
[4]
Joint United Nations Programme on HIV/AIDS. Global AIDS Update—Ending AIDS: Progress towards the 90-90-90 Targets. https://www.unaids.org/en/resources/documents/2017/20170720_Global_AIDS_update_2017
[5]
World Health Organization (2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva.
[6]
World Health Organization (2016) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva.
[7]
World Health Organization. Surveillance of HIV Drug Resistance in Adults Initiating Antiretroviral Therapy (Pre-Treatment HIV Drug Resistance) Concept Note. http://apps.who.int/iris/bitstream/10665/112802/1/9789241507196_eng.pdf?ua=1
[8]
World Health Organization (2016) Global Report on Early Warning Indicators of HIV Drug Resistance. https://www.who.int/publications/i/item/9789241511179
[9]
Taieb, F., Madec, Y., Cournil, A. and Delaporte, E. (2017) Virological Success after 12 and 24 Months of Antiretroviral Therapy in Sub-Saharan Africa: Comparing Results of Trials, Cohorts and Cross-Sectional Studies Using a Systematic Review and Meta-Analysis. PLOS ONE, 12, e0174767. https://doi.org/10.1371/journal.pone.0174767
[10]
Boerma, R.S., Boender, T.S., Bussink, A.P., Calia, J.C.J., Bertagnolio, S., Rinke de wit, T.F., et al. (2016) Suboptimal Viral Suppression Rates among HIV-Infected Children in Low- and Middle-Income Countries: A Meta-Analysis. Clinical Infectious Diseases, 63, 1645-1654. https://doi.org/10.1093/cid/ciw645
[11]
Sithole, Z., Mbizvo, E., Chonzi, P., Mungati, M., Juru, T.P., Shambira, G., et al. (2018) Virological Failure among Adolescents on ART, Harare City, 2017—A Case-Control Study. BMC Infectious Diseases, 18, Article No. 469. https://doi.org/10.1186/s12879-018-3372-6
[12]
Barth, R.E., van der Loeff, M.F., Schuurman, R., Hoepelman, A.I. and Wensing, A.M. (2010) Virological Follow-Up of Adult Patients in Antiretroviral Treatment Programmes in Sub-Saharan Africa: A Systematic Review. The Lancet Infectious Diseases, 10, 155-166. https://doi.org/10.1016/S1473-3099(09)70328-7
[13]
Boender, T.S., Sigaloff, K.C., McMahon, J.H., Kiertiburanakul, S., Jordan, M.R., Barcarolo, J., et al. (2015) Long-Term Virological Outcomes of First Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 61, 1453-1461. https://doi.org/10.1093/cid/civ556
[14]
Havens, P.L. and Gibb, D.M. (2007) Increasing Antiretroviral Drug Access for Children with HIV Infection. Pediatrics, 119, 838-845. https://doi.org/10.1542/peds.2007-0273
[15]
Sigaloff, K.C.E., Calis, J.C.J., Geelen, S.P., van Vugt, M. and Rinke de Wit, T.F. (2011) HIV-1-Resistance-Associated Mutations after Failure of First-Line Antiretroviral Treatment among Children in Resource-Poor Regions: A Systematic Review. The Lancet Infectious Diseases, 11, 769-779. https://doi.org/10.1016/S1473-3099(11)70141-4
[16]
WHO (2018) Global Action Plan on HIV Drug Resistance 2017-2021: 2018 Progress Report. http://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/
[17]
Tadesse, B.T., Tsai, O., Chala, A., Chaka, T.E., Eromo, T., Lapointe, H.R., et al. (2019) Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia. Viruses, 11, E877. https://doi.org/10.3390/v11090877
[18]
Hamers, R.L., Schuurman, R., Sigaloff, K.C., Wallis, C.L., Kityo, C., Siwale, M., et al. (2012) Effect of Pretreatment HIV-1 Drug Resistance on Immunological, Virological, and Drug-Resistance Outcomes of First-Line Antiretroviral Treatment in Sub-Saharan Africa: A Multicenter Cohort Study. The Lancet Infectious Diseases, 12, 307-317. https://doi.org/10.1016/S1473-3099(11)70255-9
[19]
UNAIDS. Nigeria (2019) Start Free, Stay Free, AIDS Free: 2018 Progress Report, UNAIDS. Nigeria. HIV and AIDS Estimates 2019 Country Fact Sheet.
[20]
Federal Ministry of Health (2016) National Implementation Plan for Scale-Up of Viral Load Testing in Nigeria. FMOH.
[21]
Federal Ministry of Health (2016) National Guidelines for HIV Prevention Treatment and Care. National AIDS and STIs Control Programme. Federal Ministry of Health, Abuja.
[22]
Joya, C., Won, S.H., Schofield, C., Lalani, T., Maves, R.C., Kronmann, K., et al. (2019) Persistent Low-Level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 69, 2145-2152. https://doi.org/10.1093/cid/ciz129
[23]
Federal Ministry of Health (2010) National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults. Federal Ministry of Health, Abuja.
[24]
FMOH Federal Ministry of Health (2020) National Guidelines for HIV Prevention Treatment and Care; National AIDS and STIs Control Programme.
[25]
Kenya Ministry of Health (2016) National AIDS/STD Control Programme (NASCOP) Dashboard.
[26]
Republic of Uganda (2016) Central Public Health Laboratories Viral Load Dashboard.
[27]
Tchouwa, G.T., Eymard-Duvernay, S., Cournil, A., Lamare, N., Serrano, L., Butel, C., et al. (2018) Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon. Clinical Medicine, 1, 21-27. https://doi.org/10.1016/j.eclinm.2018.06.005
[28]
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2018) Country Reports 2018—South Africa. https://www.unaids.org/en/regionscountries/countries/southafrica
[29]
Desta, A.A., Woldearegay, T.W., Futwi, N., Gebrehiwot, G.T., Gebru, G.G., Berhe, A.A., et al. (2020) HIV Virological Non-Suppression and Factors Associated with Non-Suppression among Adolescents and Adults on Antiretroviral Therapy in Northern Ethiopia: A Retrospective Study. BMC Infectious Diseases, 20, Article No. 4. https://doi.org/10.1186/s12879-019-4732-6
[30]
Lokpo, S.Y., Ofori-Attah, P., Ameke, L.S., Obirikorang, C., Orish, V.N., Kpene, G.E., et al. (2020) Viral Suppression and Its Associated Factors in HIV Patients on HAART: A Retrospective Study in the HO Municipality Ghana. AIDS Research and Treatment, 2020, Article ID: 9247451. https://doi.org/10.1155/2020/9247451
[31]
Humphrey, J.M., Genberg, B.L., Keter, A., Musick, B., Apondi, E., Gardner, A., Hogan, J.W. and Wools-Kaloustian, K. (2019) Viral Suppression among Children and Their Caregivers Living with HIV in Western Kenya. Journal of the International AIDS Society, 22, e2527. https://doi.org/10.1002/jia2.25272
[32]
Arpadi, S.M., Shiau, S., Gusmao, E.P.D. and Violari, A. (2017) Routine Viral Load Monitoring in HIV-Infected Infants and Children in Low- and Middle-Income Countries: Challenges and Opportunities. COMMENTARY. Journal of the International AIDS Society, 20, e25001. https://doi.org/10.1002/jia2.25001
[33]
McMahon, J.H., Elliott, J.H., Bertagnolio, S., Kubiak, R. and Jordan, M.R. (2013) Viral Suppression after 12 Months of Antiretroviral Therapy in Low- and Middle Income Countries: A Systematic Review. Bulletin of the World Health Organization, 91, 377-385. https://doi.org/10.2471/BLT.12.112946
[34]
Abioye, A.I., Soipe, A.I., Salako, A.A., Odesanya, M.O., Okuneye, T.A., Abioye, A.I., et al. (2015) Are There Differences in Disease Progression and Mortality among Male and Female HIV Patients on Antiretroviral Therapy? A Meta-Analysis of Observational Cohorts. AIDS Care, 27, 1468-1486. https://doi.org/10.1080/09540121.2015.1114994
[35]
Beckham, S.W., Beyrer, C., Luckow, P., Doherty, M., Negussie, E.K. and Baral, S.D. (2016) Marked Sex Differences in All-Cause Mortality on Antiretroviral Therapy in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Journal of the International AIDS Society, 19, Article No. 21106. https://doi.org/10.7448/IAS.19.1.21106
[36]
Cornell, M., Schomaker, M., Garone, D.B., Giddy, J., Hoffmann, C.J., Lessells, R., et al. (2012) Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLOS Medicine, 9, e1001304. https://doi.org/10.1371/journal.pmed.1001304
[37]
De Beaudrap, P., Thiam, M., Diouf, A., Toure-Kane, C., Ngom-Gueye, N.F., Vidal, N., et al. (2013) Risk of Virological Failure and Drug Resistance during First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal: Results from the ANRS 1215 Cohort. Journal of Acquired Immune Deficiency Syndromes, 62, 381-387. https://doi.org/10.1097/QAI.0b013e31827a2a7a
[38]
Ateba Ndongo, F., Texier, G., Ida Penda, C., Tejiokem, M.C., TetangNdiang, S., Ndongo, J.A. and Msellati, P. (2018) Virologic Response to Early Antiretroviral Therapy in HIV-Infected Infants. The Pediatric Infectious Disease Journal, 37, 78-84. https://doi.org/10.1097/INF.0000000000001745
[39]
Brown, K., Williams, D.B., Kinchen, S., Saito, S., Radin, E., Patel, H., et al. (2018) Status of HIV Epidemic Control among Adolescent Girls and Young Women Aged 15-24 Years—Seven African Countries, 2015-2017. Morbidity and Mortality Weekly Report (MMWR), 67, 29-32. https://doi.org/10.15585/mmwr.mm6701a6
[40]
Yehia, B.R., Rebeiro, P., Althoff, K.N., Agwu, A.L., Horberg, M.A., Samji, H., et al. (2015) Impact of Age on Retention in Care and Viral Suppression. Journal of Acquired Immune Deficiency Syndromes, 68, 413-419. https://doi.org/10.1097/QAI.0000000000000489
[41]
Bulage, L., Ssewanyana, I., Nankabirwa, V., Nsubuga, F., Kihembo, C., Pande, G., et al. (2017) Factors Associated with Virological Non Suppression among HIV Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infectious Diseases, 17, Article No. 326. https://doi.org/10.1186/s12879-017-2428-3
[42]
Peltzer, K. and Pengpid, S. (2013) Socioeconomic Factors in Adherence to HIV Therapy in Low- and Middle-Income Countries. Journal of Health, Population and Nutrition, 31, 150-170. https://doi.org/10.3329/jhpn.v31i2.16379
[43]
Hailu, G.G., Hagos, D.G., Hagos, A.K., Wasihun, A.G. and Dejene, T.A. (2018) Virological and Immunological Failure of HAART and Associated Risk Factors among Adults and Adolescents in the Tigray Region of Northern Ethiopia. PLOS ONE, 13, e0196259. https://doi.org/10.1371/journal.pone.0196259
[44]
Kiweewa, F., Esber, A., Musingye, E., Reed, D., Crowell, T.A., Cham, F., et al. (2019) HIV Virologic Failure and Its Predictors among HIV-Infected Adults on Antiretroviral Therapy in the African Cohort Study. PLOS ONE, 14, e0211344. https://doi.org/10.1371/journal.pone.0211344
[45]
World Health Organization (2015) Antiretroviral Therapy (ART) Coverage among All Age Groups. http://www.who.int/gho/hiv/epidemic_response/ART_text/en/
[46]
Kanthula, R., Rossouw, T.M., Feucht, U.D., van Dyk, G., Beck, I.A., Silverman, R., et al. (2017) Persistence of HIV Drug Resistance among South African Children Given Nevirapine to Prevent Mother-to-Child-Transmission. AIDS, 31, 1143-1148. https://doi.org/10.1097/QAD.0000000000001446
[47]
Kyaw, N.T.T., Harries, A.D., Kumar, A.M.V., Oo, M.M., Kyaw, K.W.Y., Win, T., et al. (2017) High Rate of Virological Failure and Low Rate of Switching to Second-Line Treatment among Adolescents and Adults Living with HIV on First Line ART in Myanmar, 2005-2015. PLOS ONE, 12, e0171780. https://doi.org/10.1371/journal.pone.0171780
[48]
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration (2019) Incidence of Switching to Second Line Antiretroviral Therapy and Associated Factors in Children with HIV: An International Cohort Collaboration. The Lancet HIV, 6, E105-E115.
[49]
Chhim, K., Mburu, G., Tuot, S., Sopha, R., Khol, V., Chhoun, P., et al. (2018) Factors Associated with Viral Non-Suppression among Adolescents Living with HIV in Cambodia: A Cross-Sectional Study. AIDS Research and Therapy, 15, Article No. 20. https://doi.org/10.1186/s12981-018-0205-z
[50]
Rangoran, S., Colby, D.J., Truong, G.L., Bui, D.D., Nguyen, H.H., Tou, P.B., et al. (2016) Factors Associated with HIV Viral Load Suppression on Antiretroviral Therapy in Vietnam. Journal of Virus Eradication, 2, 94-101. https://doi.org/10.1016/S2055-6640(20)30466-0
